The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study
The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study
复制标题
DOI：
10.1002/hup.421
复制
发表时间：
2002-10-01
影响因子：
1.7
通讯作者：
Grunhaus, L
中科院分区：
文献类型：
--
作者：
Dannon, PN;Iancu, I;Grunhaus, L
背景与目的选择性5-羟色胺再摄取抑制剂（SSRIs）是目前治疗惊恐障碍的一线药物，但仍有高达30%的患者对SSRIs无反应或因不良反应而退出治疗。瑞波西汀是一种选择性去甲肾上腺素再摄取抑制剂（选择性NRI），可有效治疗抑郁症，并可缓解抑郁症相关的焦虑。本研究旨在。调查的疗效reboxaline在治疗患者的惊恐障碍谁没有回应SSRIs.Method在这个为期6周，开放标签的研究，29名成人门诊惊恐障碍谁以前没有回应SSRI治疗reboxaline 2毫克/天，滴定到最大8毫克/天，在第一个10天。采用惊恐自评问卷（PSQ）、汉密尔顿焦虑量表（HAM-A）、汉密尔顿抑郁量表（HRSD）和功能总评量表（GAF）评定疗效。观察到每日惊恐发作次数以及测量焦虑、抑郁和功能的量表有显著改善（p < 0.001）。Reboxastine通常耐受良好。5例患者退出，由于不良事件。结论瑞波西汀似乎是有效的SSRI难治性惊恐障碍患者的治疗，并值得进一步的临床研究。版权所有（C）2002约翰威利父子有限公司
Background and Objective Selective serotonin reuptake inhibitors (SSRIs) are currently the first-line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibitor (selective NRI), is effective in treating depression and may alleviate depression-related anxiety. This study aimed to. investigate the efficacy of reboxetine in the treatment of patients with panic disorder who did not respond to SSRIs.Method In this 6-week, open-label study, 29 adult outpatients with panic disorder who had previously failed to respond to SSRI treatment received reboxetine 2 mg/day, titrated to a maximum of 8 mg/day over the first 10 days. Efficacy was assessed using the Panic Self-Questionnaire (PSQ), the Hamilton Rating Scale for Anxiety (HAM-A), the 17-item Hamilton Rating Scale for Depression (HRSD) and the Global Assessment of Functioning (GAF) Scale.Results The 24 patients who completed the study responded well to reboxetine treatment. Significant improvement (p < 0.001) was observed in the number of daily panic attacks, and on the scales measuring anxiety, depression and functioning. Reboxetine was generally well tolerated. Five patients withdrew due to adverse events.Conclusions Reboxetine appears to be effective in the treatment of SSRI-refractory panic disorder patients and warrants further clinical investigation. Copyright (C) 2002 John Wiley Sons, Ltd.